Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical effects of the dichloro and monochlorophenyl analogues of diamino pyrimidine: antagonists of folic acid.

Literature DB >> 13201645

Clinical effects of the dichloro and monochlorophenyl analogues of diamino pyrimidine: antagonists of folic acid.

M L MURPHY, R R ELLISON, D A KARNOFSKY, J H BURCHENAL.

Abstract

Entities: Chemical

Keywords: LEUKEMIA/therapy; PYRIMIDINES/therapeutic use

Mesh：

Substances：

Year: 1954 PMID： 13201645 PMCID： PMC1072559 DOI： 10.1172/JCI103016

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

× No keyword cloud information.

13 in total

1. Daraprim, clinical trials and pharmacology.

Authors: L G GOODWIN
Journal: Trans R Soc Trop Med Hyg Date: 1952-09 Impact factor: 2.184

2. Antagonists of nucleic acid derivatives. VII. 2, 4-Diaminopyrimidines.

Authors: G H HITCHINGS; E A FALCO; H VANDERWERFF; P B RUSSELL; G B ELION
Journal: J Biol Chem Date: 1952-11 Impact factor: 5.157

3. Studies on the compound 50-63.

Authors: G R COATNEY; A V MYATT; T HERNANDEZ; G M JEFFERY; W C COOPER
Journal: Trans R Soc Trop Med Hyg Date: 1952-09 Impact factor: 2.184

4. Daraprim-experimental chemotherapy.

Authors: I M ROLLO
Journal: Trans R Soc Trop Med Hyg Date: 1952-09 Impact factor: 2.184

5. Effect of various compounds on the Ehrlich ascites carcinoma.

Authors: K SUGIURA
Journal: Cancer Res Date: 1953-06 Impact factor: 12.701

6. Daraprim (B.W. 50-63) a new antimalarial; trials in human volunteers.

Authors: L G GOODWIN
Journal: Br Med J Date: 1952-04-05

7. A simple method for determination of levels of amethopterin in blood and urine.

Authors: J H BURCHENAL; G B WARING; R R ELLISON; H C REILLY
Journal: Proc Soc Exp Biol Med Date: 1951-11

8. The effects of the folic acid antagonists and 2,6-diaminopurine on neoplastic disease, with special reference to acute leukemia.

Authors: J H BURCHENAL; D A KARNOFSKY; E M KINGSLEY-PILLERS; C M SOUTHAM; W P L MYERS; G C ESCHER; L F CRAVER; H W DARGEON; C P RHOADS
Journal: Cancer Date: 1951-05 Impact factor: 6.860

9. Hyperpigmentation in acute leukemia treated with folic acid antagonists.

Authors: H A WAISMAN; J B RICHMOND; A A ZIMMERMAN
Journal: Proc Soc Exp Biol Med Date: 1950-11

10. The pharmacological properties of 2, 4-diamino-5-p-chlorophenyl-6-ethylpyrimidine, daraprim.

Authors: L H SCHMIDT; H B HUGHES; I G SCHMIDT
Journal: J Pharmacol Exp Ther Date: 1953-01 Impact factor: 4.030

10 in total

1. SYMPOSIUM on anti-tumour agents: cytostatic agents.

Authors:
Journal: Proc R Soc Med Date: 1957-01

2. The chemotherapy of malignant disease.

Authors: R B SCOTT
Journal: Br Med J Date: 1958-01-04

3. Methodichlorophen as anti-tumor drug.

Authors: L A Price; J H Goldie; B T Hill
Journal: Br Med J Date: 1975-04-05

4. An enzyme inhibition assay for 2,4-diamino-5-(3'4'-dichlorophenyl)-6-methylpyrimidine (DDMP,NSC 19494).

Authors: A H Calvert; J S Cridland; K R Harrap
Journal: J Clin Pathol Date: 1977-12 Impact factor: 3.411

5. Initial clinical experience with a simultaneous combination of 2,4-diamino-5(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP) with folinic acid.

Authors: P Alberto; R Peytremann; R Medenica; M Beretta-Piccoli
Journal: Cancer Chemother Pharmacol Date: 1978 Impact factor: 3.333

6. Phase I clinical trial and pharmacology of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (metoprine) (DDMP) and folinic acid (CF).

Authors: R de Jager; D Dupont; J J Rodzynek; C Dorlet; G Lagrange
Journal: Cancer Chemother Pharmacol Date: 1981 Impact factor: 3.333

7. Phase II clinical trial of DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine) and folinic acid (CF) in solid tumors.

Authors: R de Jager; A Brugarolas; M Hansen
Journal: Cancer Chemother Pharmacol Date: 1981 Impact factor: 3.333

8. Kinetics of metoprine, a lipid-soluble antifolate.

Authors: B R Jones; C S Gordon; J Umans; M M Reidenberg; C W Young
Journal: Br J Clin Pharmacol Date: 1981-11 Impact factor: 4.335

9. Phase I clinical trial and human pharmacokinetics of 2,4-diamino-5-adamantyl-6-methyl pyrimidine ethane sulfonate (DAMP-ES): a lipid-soluble antifolate.

Authors: P J Creaven; S F Zakrzewski; W R Greco; S Madajewicz; A Mittelman; J E Pontes; C Karakousis; H Takita; A Proefrock
Journal: Cancer Chemother Pharmacol Date: 1988 Impact factor: 3.333

10. Studies concerned with overcoming resistance to methotrexate: a comparison of the effects of methotrexate and 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (BW50197) on the colony forming ability of L5178Y cells.

Authors: B T Hill; J H Goldie; L A Price
Journal: Br J Cancer Date: 1973-09 Impact factor: 7.640

10 in total